Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBIT Margin (2016 - 2025)

Vanda Pharmaceuticals' EBIT Margin history spans 16 years, with the latest figure at 70.53% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 5120.0% year-over-year to 70.53%; the TTM value through Dec 2025 reached 69.95%, down 4950.0%, while the annual FY2025 figure was 69.95%, 4950.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 70.53% at Vanda Pharmaceuticals, down from 55.61% in the prior quarter.
  • Across five years, EBIT Margin topped out at 18.22% in Q2 2021 and bottomed at 81.99% in Q1 2025.
  • The 5-year median for EBIT Margin is 14.09% (2023), against an average of 16.28%.
  • The largest annual shift saw EBIT Margin soared 1672bps in 2021 before it plummeted -6253bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 12.7% in 2021, then decreased by -19bps to 10.28% in 2022, then plummeted by -252bps to 15.67% in 2023, then fell by -23bps to 19.33% in 2024, then tumbled by -265bps to 70.53% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EBIT Margin are 70.53% (Q4 2025), 55.61% (Q3 2025), and 73.21% (Q2 2025).